Presentation is loading. Please wait.

Presentation is loading. Please wait.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

Published byRafaela Sousa Modified over 4 years ago

Similar presentations

Presentation on theme: "Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3."— Presentation transcript:

1 Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy.
Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. A–E, MC38 MHC class I–deficient (M1 KO) tumor-bearing mice (n = 6/group) were treated with rIL21 (10 μg/mouse) by intratumoral injection and/or anti–PD-1/anti–Tim-3 by i.p. injection. A–D, Mice were treated with anti-CD8 to deplete CD8+ T cells every 3 days. B, IFNγ expression on NK cells was analyzed by flow cytometry. C, Tumor growth was measured using a metric caliper 2 to 3 times per week. D, Survival rate in each group is represented. E, Mice (n = 6/group) were treated with anti-NK1.1 every 3 days for depleting NK cells by i.p. injection, and tumor growth was measured using a metric caliper 2 to 3 times per week. The data in B were analyzed by Student t test. The data in C and E were analyzed by a two-way ANOVA with a Bonferroni multiple comparison test. The data in D were analyzed using a log-rank Mantel–Cox test (conservative). *, P < 0.05; **, P < 0.01; ***; P < 0.001; ****, P < The data are representative of at least two independent experiments that included six mice per group. All values represent the mean \pm $ SEM. Hyungseok Seo et al. Cancer Immunol Res 2018;6: ©2018 by American Association for Cancer Research

Download ppt "Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3."

Similar presentations

Synergistic antitumor effect of anti-CD40/CpG and 14

Synergistic antitumor effect of anti-CD40/CpG and 14
Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.
Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs
Uptake of T-MPs for DC maturation and antigen presentation.

Uptake of T-MPs for DC maturation and antigen presentation.
Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.

Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.
Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.
Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses  William H.D. Hallett, Erik Ames, Maite.

Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses  William H.D. Hallett, Erik Ames, Maite.
Vascular HR ligand expression depends on tumor anatomical location.

Vascular HR ligand expression depends on tumor anatomical location.
by Adrienne Sallets, Sophie Robinson, Adel Kardosh, and Ronald Levy

by Adrienne Sallets, Sophie Robinson, Adel Kardosh, and Ronald Levy
In vivo validation of effects of combination therapies on subpopulation composition. In vivo validation of effects of combination therapies on subpopulation.

In vivo validation of effects of combination therapies on subpopulation composition. In vivo validation of effects of combination therapies on subpopulation.
Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.
Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. Effect.

Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. Effect.
Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.

Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.
Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.
CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.
Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.
Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented growth inhibition in WT mice. Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented.

Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented growth inhibition in WT mice. Ablation of PD-L1 in edited T3 sarcoma cells leads to augmented.

Similar presentations

Ads by Google